Workshop / Mentoring
We believe in transferring knowledge, and we do it with passion.
We excel at explaining patterns, as well as spotting the details that make the difference—the ones that drive decision-making, for better or worse. We are priviledged to work with incredibly talented leadership teams in innovative Life Sciences and High Growth / High Risk from very early research stage to commercial stage and be exposed in our work to deep, longitudinal, operational insight in relation to decision making.
"How did you know ?" We often get called "magic wisdom" or "oracle". There is likely no such thing though. Rather, what we see are clear patterns in this field, often difficult to identify early on, though, as they are tied to the learning curve of individuals, and collectively, organisation. By the time stakeholders come to realization, it is often too late to reverse the effects.
High Growth / High Risk and implications of innovative Life Sciences remains poorly understood at policy making level. Small and mid-sized innovative ventures have neither the bandwidth nor the mindset to raise their profile with policymarkers. They are hands-on people and the set of constraint they deal with (time, cash, people), is quite opposite of the large recurring cash-flows companies or public bodies. As a result, the SME perspective—their insights—remain silent. Hidden.
But the price of this silence is high. Ultimately, it transfers to the end consumers or payers. On particularly underserved topics, or whenever we are called upon, we take the pen, the mic, and explain what we see—and, more importantly, the way forward.

Workshop
For whom ?
- Innovative ventures
- Incubators / Accelerators
- Tech Transfers Offices
- Master´s programs /MBAs
Some recurrent topics :
- Who´s in for High Growth / High Risk ?
- Cash vs. Science : what´s driving us?
- Dealing with uncertainty
- Cracking the innovative start-up code
- Beyond Financial Terms
- Value of Science (rNPV) or Value of Cash (VC model) ?
- From idea to company : early exposure to decision making and governance (term sheet + shareholder agreement negotiation)
- In the mind and mandate of a VC
- Pitch feedback circle
- Market analysis from the investors´ perspective
- How to think "Market-to-Bench"

Mentoring
For whom ?
- Pre-inception teams (via incubators)
- Young ventures
- Mature ventures
- Innovative ventures shifting strategy
- Incubator/Accelerator personnel
- NGOs exposed to innovative Life Sciences
Some recurrent topics:
- Strategic questions related to financing, business case, incentives, negotiation or narrative/cohesiveness designed to be addressed within 1 to 3 hours
- Pitch deck/Valuation review
- Equity story vs. Investor type
- Asset story vs. Exit type
- Assessing the stage of readiness of companies, teams and assets in High Growth / High Risk at R&D stage
- Adding the investor´s perspective to the scope of analysis/work
- Where is cash available High Growth/High Risk, and what is it available for ?
- Where is pharma heading ? What to adjust and how ?

Roundtable
For whom ?
- BD, CRO and Biotech Associations
- Life Sciences Conferences
- Incubator/Accelerator Events
- Brainstorming days of large companies or public institutions seeking to understand the "SME perspective"
- NGOs and Foundations
Some topics where we were asked to share our views:
- Financing in a changing landscape
- R&D vs. AI, where does the value come from ?
- Real and perceived hurdles in consideration of the full value of antibiotics: How can we overcome the roadblocks?
- How to value Innovative CROs ?
- Financing and operational challenges in infectious diseases
- The innovative SME perspective
- How to adjust European Capital Markets to the specific needs of innovative High Growth / High Risk ventures
- Viability of small cap segments on stock exchanges for innovative Life Sciences ventures
- Where is innovation and what are the gaps in AMR ?

Services to incubators
Pre-inception and baby innovative High Growth / High Risk and Life Sciences companies need the tailored support of incubators, dedicated initiatives and sponsors.
Our services to incubators are delivered with the same level of professionalism as any other customer we serve within the ecosystem. In fact, early stage is one of our specialty fields.
Working with young ventures and entrepreneurs-in-the-making demands extra-diligence. We help them prepare for the long game and determine if this path is right for them. Done well, this creates a steep learning curve for founders, strong differentiation for incubators, and well-invested taxpayer or sponsor money.
We have consistently observed—and heard directly from founders
—
that a needs-first approach, centered on the realities of innovative High Growth / High Risk and Life Sciences, delivers far more value than “supplier-oriented” models that treat start-ups as business leads for service providers.
We also caution against using conversion metrics like incorporation rates as primary KPIs. In this innovative, patent-protected field requiring multiple financing rounds, a single misstep around incorporation can derail a venture’s long-term potential. What policy makers aim to create here is technological progress and leadership with economic return in the form of taxes and jobs—not small, short-lived, loss-making companies, which is equally frustrating for entrepreneurs and investors. That´s our focus too.